Swiss Biotech Day: Geneva based Light Chain Bioscience is developing bi-specifics that integrate two light chains into its structure with the goal of having a more native format

CEO Nicolas Fischer describes the rationale of designing bi-specifics this way, and walks us through the company's programs, which mostly have a CD47 or CD28 backbone.